Repatha cardiovascular risk reduction has reached a new milestone in the fight against heart disease. Amgen recently announced groundbreaking results from a subgroup analysis of the Phase 3 VESALIUS-CV clinical trial, demonstrating that Repatha® (evolocumab) significantly reduces the risk of first-time major adverse cardiovascular events (MACE) in high-risk primary prevention patients.
The study focused on a subgroup of 3,655 patients who were at increased risk for heart complications but had no known significant atherosclerosis. All participants in this specific analysis also had diabetes, a major contributor to vascular issues. Over a median follow-up of 4.8 years, the data showed that adding Repatha to optimized statin therapy led to a 31% reduction in the composite primary endpoint of coronary heart disease (CHD) death, myocardial infarction (heart attack), or ischemic stroke.
This 31% Repatha cardiovascular risk reduction was also mirrored in the dual composite primary endpoint, which included ischemia-driven revascularization, further proving the drug’s efficacy in preventing the initial onset of clinical heart disease.
Achieving Intensive LDL-C Lowering Goals
One of the most striking aspects of the trial was the level of cholesterol control achieved. Patients treated with Repatha reached a median LDL-C (bad cholesterol) level of just 44 mg/dL, compared to 105 mg/dL in the placebo group.
The evidence is unequivocal: intensive LDL-C lowering with Repatha significantly reduces the risk of major CV events for high-risk patients.
Jay Bradner, M.D., executive vice president of Research and Development at Amgen.
Why This Matters for Primary Prevention
For years, Repatha has been a staple in “secondary prevention”—treating patients who have already suffered a heart attack or stroke. However, these new findings reinforce the benefit of earlier initiation. By utilizing Repatha cardiovascular risk reduction strategies before plaque buildup becomes advanced, healthcare providers can potentially prevent the first life-altering event from ever occurring.
High LDL-C is considered one of the most modifiable risk factors for cardiovascular disease. According to the American Heart Association, maintaining low LDL levels is critical for long-term vascular health. This study positions Repatha as the only PCSK9 inhibitor to demonstrate such significant results in both primary and secondary prevention settings.
Key Findings from the VESALIUS-CV Subgroup:
- Heart Attack Risk: Reduced by 31% (numerical reduction).
- Ischemic Stroke Risk: Reduced by 33% (numerical reduction).
- Ischemia-Driven Revascularization: Reduced by 34% (numerical reduction).
- All-Cause Death: Trended lower with a 24% relative risk reduction.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Key Clinical Outcomes
| Endpoint Category | Clinical Endpoint | Repatha (Evolocumab) + SOC | Placebo + SOC | Relative Risk Reduction (RRR) |
| Primary Endpoints | 3-Point MACE (CHD Death, MI, or Stroke) | 6.2% | 8.0% | 31%* |
| 4-Point MACE (3-P MACE + Ischemia-driven Revascularization) | 13.4% | 16.2% | 31%* | |
| Secondary Endpoints | Heart Attack (MI) | Numerical Reduction | – | 31% |
| Ischemic Stroke | Numerical Reduction | – | 33% | |
| Ischemia-driven Revascularization | Numerical Reduction | – | 34% | |
| Cardiovascular (CV) Death | Numerical Trend | – | 32% | |
| All-Cause Death | 7.9% | 9.7% | 24% | |
| Lipid Efficacy | Median Achieved LDL-C (at 96 weeks) | 44 mg/dL | 105 mg/dL | ~58% Lower |
Trial Participant Characteristics
- Total Patients in Analysis: 3,655
- Key Inclusion: High-risk patients with diabetes and no known significant atherosclerosis.
- Median Follow-up: 4.8 years.
- Baseline Therapy: Over 85% of patients were on moderate-to-high intensity statin therapy at the start of the trial.
